» Articles » PMID: 36337819

Migraine and Current Pharmacologic Management

Abstract

In light of the multiple pharmacologic alternatives for migraine management, the adverse effects associated with different treatment regimens, and their varying efficacy, it is vital to undertake ongoing evaluations and seek a tailored therapeutic strategy. This case report describes two patients who presented with classic migraine headaches, with the first responding to both abortive and prophylactic migraine medications and the second, with status migrainosus-like presentation, responding to the newer antimigraine agents. We also examined current pharmacological therapeutic options and existing recommendations, analyzing their strengths and weaknesses. This case review exemplifies how treatment in the last 10 years and success in medications used for abortive and prophylactic therapy are evolving from the older agents to newer agents like the recently approved calcitonin gene receptor protein monoclonal antibody inhibitors.

Citing Articles

Overview of Median Arcuate Ligament Syndrome: A Narrative Review.

Upshaw W, Richey J, Ravi G, Chen A, Spillers N, Ahmadzadeh S Cureus. 2023; 15(10):e46675.

PMID: 37942382 PMC: 10629207. DOI: 10.7759/cureus.46675.


Impact of Adverse Childhood Experiences on Resilience and School Success in Individuals With Autism Spectrum Disorder and Attention-Deficit Hyperactivity Disorder.

Adaralegbe N, Okobi O, Omar Z, Segun E, Evbayekha E, Abolurin A Cureus. 2022; 14(11):e31907.

PMID: 36579285 PMC: 9792122. DOI: 10.7759/cureus.31907.

References
1.
Wang X, Chen Y, Song J, You C . Efficacy and Safety of Monoclonal Antibody Against Calcitonin Gene-Related Peptide or Its Receptor for Migraine: A Systematic Review and Network Meta-analysis. Front Pharmacol. 2021; 12:649143. PMC: 8045977. DOI: 10.3389/fphar.2021.649143. View

2.
Bruloy E, Sinna R, Grolleau J, Bout-Roumazeilles A, Berard E, Chaput B . Botulinum Toxin versus Placebo: A Meta-Analysis of Prophylactic Treatment for Migraine. Plast Reconstr Surg. 2018; 143(1):239-250. DOI: 10.1097/PRS.0000000000005111. View

3.
Sutherland H, Albury C, Griffiths L . Advances in genetics of migraine. J Headache Pain. 2019; 20(1):72. PMC: 6734342. DOI: 10.1186/s10194-019-1017-9. View

4.
Vandervorst F, Van Deun L, Van Dycke A, Paemeleire K, Reuter U, Schoenen J . CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs. J Headache Pain. 2021; 22(1):128. PMC: 8547103. DOI: 10.1186/s10194-021-01335-2. View

5.
Overeem L, Raffaelli B, Mecklenburg J, Kelderman T, Neeb L, Reuter U . Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis. CNS Drugs. 2021; 35(8):805-820. PMC: 8354912. DOI: 10.1007/s40263-021-00834-9. View